| abstract |
The present invention relates to novel safe attenuated Pseudomonas aeruginosa strains obtained by isolating Pseudonomas aeruginosa in a pure state according to Fisher-Devlin immunotype and then repeatedly purifying the isolated strain, particularly CFCPA 10142 (KCCM 10029), CFCPA 20215 (KCCM 10030), CFCPA 30720 (KCCM 10031), CFCPA 40057 (KCCM 10032), CFCPA 50243 (KCCM 10033), CFCPA 60534 (KCCM 10034) and CFCPA 70018 (KCCM 10035) strains. In addition, the present invention relates to a vaccine for immunization against Pseudomonas aeruginosa infection which includes cell wall proteins having molecular weight ranging from 10,000 to 100,000 , obtained from the attenuated Pseudomonas aeruginosa strains, a therapeutic agent for treating Pseudomonas aeruginosa infection containing immunoglobulin(s) induced by the cell wall proteins in an experimental animal, and methods of their preparation. The cell wall protein component of the attenuated strain is non-pathogenic and safe and exhibits excellent antibody formation and is useful for preparation of a vaccine and therapeutic agent. The cell wall proteins exhibit an excellent cross-protective capacity for various Pseudomonas aeruginosa strains and a superior antibody inducing property. |